Simulations Plus vs Doximity: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Simulations Plus Inc (SLP)

Q3 202617 Jun – 24 Jul 2026

▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.
The buyout is the single biggest force setting SLP's price now.
Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.
It shows the technology value underpinning the company being acquired.
Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.
It gives the latest financial health picture behind the buyout.
Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.
It is the main risk factor that could complicate or delay the deal.

July 202617 Jun – 24 Jul 2026

▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.
The buyout is the single biggest force setting SLP's price now.
Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.
It shows the technology value underpinning the company being acquired.
Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.
It gives the latest financial health picture behind the buyout.
Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.
It is the main risk factor that could complicate or delay the deal.

Latest17 Jun – 24 Jul 2026

▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.
The buyout is the single biggest force setting SLP's price now.
Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.
It shows the technology value underpinning the company being acquired.
Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.
It gives the latest financial health picture behind the buyout.
Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.
It is the main risk factor that could complicate or delay the deal.

Doximity Inc (DOCS)

Q3 202629 Jun – 28 Aug 2026

▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.
This is the single biggest new event of the period and the main reason DOCS moved sharply higher.
AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.
It explains why investors are optimistic about the AI strategy despite near-term costs.
AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.
It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.
AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.
It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

July 202629 Jun – 28 Aug 2026

▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.
This is the single biggest new event of the period and the main reason DOCS moved sharply higher.
AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.
It explains why investors are optimistic about the AI strategy despite near-term costs.
AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.
It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.
AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.
It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

Latest29 Jun – 28 Aug 2026

▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.
This is the single biggest new event of the period and the main reason DOCS moved sharply higher.
AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.
It explains why investors are optimistic about the AI strategy despite near-term costs.
AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.
It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.
AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.
It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.